Teva Pharmaceutical Industries Limited (FRA:TEV)
Germany · Delayed Price · Currency is EUR | Market Cap | 31.81B +96.8% |
| Revenue (ttm) | 15.05B +4.4% |
| Net Income | 1.36B |
| EPS | 1.16 |
| Shares Out | n/a |
| PE Ratio | 23.44 |
| Forward PE | 14.40 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 313 |
| Open | 26.90 |
| Previous Close | 27.00 |
| Day's Range | 26.90 - 27.70 |
| 52-Week Range | 12.90 - 31.60 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 29, 2026 |
About FRA:TEV
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
News
Teva price target raised to $44 from $42 at Piper Sandler
Piper Sandler analyst David Amsellem raised the firm’s price target on Teva (TEVA) to $44 from $42 and keeps an Overweight rating on the shares. The firm cites the inclusion…
Teva's Turnaround Is Working. Here's the 1 Thing That Could Send It Soaring Another 50%.
Teva's pivot toward branded drugs is benefiting the company's underlying performance and its stock price. While shares have pulled back recently, another big catalyst could play out in the years ahead...
Wall Street Thinks Teva Can Soar Over 60%. Here's Why Analysts Are Right.
Teva's business is shifting away from generic drugs toward branded drugs. Operating margins could soar through next year, boosting earnings potential.
Why Teva Pharmaceutical Stock Is a Buy Despite Trump Tariff Threat
Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply
Trump plans tariffs of up to 200% on imported generic drugs after a two-year grace period aimed at encouraging U.S. manufacturing. But thin profit margins make tariffs harder to absorb than for brande...
Noteworthy ETF Outflows: EFA, SPOT, NBIS, TEVA
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares MSCI EAFE ETF (Symbol: EFA) where we have detected an approxim...
A Look at Teva Pharmaceutical Industries Ltd (TEVA) After 3.2% Decline -- GF Value $20. ...
A Look at Teva Pharmaceutical Industries Ltd (TEVA) After 3.2% Decline -- GF Value $20.01 vs Price $31.00
Teva (TEVA) Sees 2% Rise After Seven-Day Decline
Teva (TEVA) Sees 2% Rise After Seven-Day Decline
Colin Cieszynski's Past Picks: First Quantum Minerals, Teva Pharmaceuticals & BMO Global Gold Index
Colin Cieszynski, portfolio manager & chief market strategist at SIA Wealth Management, discusses his past stock picks and how they're doing in the market today
Teva (TEVA) Lawsuit Against Eli Lilly Revived by Appeals Court
Teva (TEVA) Lawsuit Against Eli Lilly Revived by Appeals Court
US appeals court revives Teva lawsuit over Lilly osteoporosis drug
A U.S. appeals court on Monday revived a lawsuit brought by generic drugmaker Teva Pharmaceuticals that accuses Eli Lilly of breaching a settlement agreement that allowed Teva to market a generic vers...
Teva Pharmaceutical Industries' Anti-IL-15 Antibody Shows Promise in Vitiligo Study
Teva Pharmaceutical Industries NYSE: TEVA said its internally developed anti-IL-15 antibody produced encouraging 24-week efficacy results in a phase 1b proof-of-concept study for vitiligo, as the comp...
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
Novartis AG maintains a highly profitable portfolio of innovative medicines with significant net margins. Teva Pharmaceutical Industries is executing a turnaround focused on biosimilars and high-growt...
Teva (TEVA) Secures Global Licensing Deal for Biosimilar Ocrevus
Teva (TEVA) Secures Global Licensing Deal for Biosimilar Ocrevus
Teva And Polpharma Enter Licensing Agreement For Ocrevus Biosimilar Candidate In Multiple Sclerosis
(RTTNews) - Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (TEVA), and Polpharma Biologics International AG announced on Thursday that they have entered in...
Teva (TEVA) Expands Biosimilar Portfolio in Canada with New Agreement
Teva (TEVA) Expands Biosimilar Portfolio in Canada with New Agreement
Teva And Samsung Bioepis Enter Commercialization Agreement For OPUVIZ In Canada
(RTTNews) - On Thursday, Teva Pharmaceutical Industries Ltd. (TEVA) and Samsung Bioepis Co., Ltd., a unit of Samsung Epis Holdings Co. Ltd. (0126Z0.KS), announced that they have entered into a license...
Teva, Polpharma enter global licensing agreement for Ocrevus biosimilar
Teva (TEVA) Pharmaceuticals and Polpharma Biologics International announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ propo...
Teva And Polpharma Biologics Ink Global Licensing Deal For Ocrevus Biosimilar
(RTTNews) - Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (TEVA) and Polpharma Biologics International AG announced Thursday a global licensing agreement ...
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
TEL AVIV, Israel & ZUG, Switzerland--(BUSINESS WIRE)--Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics Interna...
Teva, Polpharma Biologics announce global licensing agreement
Teva (TEVA) Pharmaceuticals International, a subsidiary of Teva, and Polpharma Biologics announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Pol...
Teva, Samsung Bioepis enter commercialization agreement for OPUVIZ
Teva (TEVA) Pharmaceutical Industries and Samsung Bioepis announced that the companies have entered into a license and commercialization agreement for OPUVIZ, a biosimilar referencing Eylea, in Canada...
A Look at Teva Pharmaceutical Industries Ltd (TEVA) After 4.1% Decline -- GF Value $20. ...
A Look at Teva Pharmaceutical Industries Ltd (TEVA) After 4.1% Decline -- GF Value $20.26 vs Price $33.24
Teva (TEVA) Advances Vitiligo Treatment into Phase 2b Study
Teva (TEVA) Advances Vitiligo Treatment into Phase 2b Study
Teva Pharmaceutical Industries Transcript: Study result
A phase I-B study of anti-IL-15 in vitiligo showed 42% of patients achieved ≥50% facial improvement and 21% achieved ≥75% at 24 weeks, with high patient satisfaction and favorable safety. The antibody's quarterly dosing and efficacy compare well to oral JAKs, and broader development in related diseases is underway.